Sentiment Trading

4D Molecular Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for genetic diseases, with a global presence and potential for long-term growth.

4D Molecular Therapeutics has received FDA RMAT designation for its drug candidate 4D-150, a potential treatment for Diabetic Macular Edema, which could expedite its development and review.